INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Submission of Matters to a Vote of Security Holders

Broker Non-Votes

ME Staff 8-k

8 years ago

INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 23, 2017, INC Research Holdings, Inc. (the Company) held its
2017 Annual Meeting of Stockholders (the Meeting). The certified
results of the matters voted upon at the Meeting, which are more
fully described in the Companys proxy statement, are as follows:

1. Election of Directors. In an uncontested election, each of the
following Class III nominees was elected to the Board of Directors
for a term expiring at the 2020 annual meeting of stockholders or
until their successors have been elected and qualified. The
following table reflects the voting results for each nominee:



Nominee	For	Against	Abstain	Broker Non-Votes
Richard N. Kender	49,986,806	84,033	55,807	1,842,644
Kenneth F. Meyers	46,791,561	278,278	56,807	1,842,644
Matthew E. Monaghan	46,791,587	278,252	56,807	1,842,644
David Y. Norton	46,964,273	105,415	56,958	1,842,644

2. Approval, on an advisory (nonbinding) basis, of the resolution
regarding executive compensation:

This proposal was approved on an advisory (non-binding) basis.

3. Approval of the Management Incentive Plan, including the
material terms of the performance goals applicable to awards
granted under the Plan in accordance with Internal Revenue Code
Section 162(m):

This proposal was approved.

4. Ratification of the appointment of the Company’s independent
auditors Deloitte Touche LLP:

This proposal was ratified.

About INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Recent Trading Information
INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) closed its last trading session up +0.25 at 55.95 with 679,470 shares trading hands.